Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials

Epigenetic alternations concern heritable yet reversible changes in histone or DNA modifications that regulate gene activity beyond the underlying sequence. Epigenetic dysregulation is often linked to human disease, notably cancer. With the development of various drugs targeting epigenetic regulator...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yuan, He, Cai, Wang, Manni, Ma, Xuelei, Mo, Fei, Yang, Shengyong, Han, Junhong, Wei, Xiawei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915746/
https://www.ncbi.nlm.nih.gov/pubmed/31871779
http://dx.doi.org/10.1038/s41392-019-0095-0
_version_ 1783480087973199872
author Cheng, Yuan
He, Cai
Wang, Manni
Ma, Xuelei
Mo, Fei
Yang, Shengyong
Han, Junhong
Wei, Xiawei
author_facet Cheng, Yuan
He, Cai
Wang, Manni
Ma, Xuelei
Mo, Fei
Yang, Shengyong
Han, Junhong
Wei, Xiawei
author_sort Cheng, Yuan
collection PubMed
description Epigenetic alternations concern heritable yet reversible changes in histone or DNA modifications that regulate gene activity beyond the underlying sequence. Epigenetic dysregulation is often linked to human disease, notably cancer. With the development of various drugs targeting epigenetic regulators, epigenetic-targeted therapy has been applied in the treatment of hematological malignancies and has exhibited viable therapeutic potential for solid tumors in preclinical and clinical trials. In this review, we summarize the aberrant functions of enzymes in DNA methylation, histone acetylation and histone methylation during tumor progression and highlight the development of inhibitors of or drugs targeted at epigenetic enzymes.
format Online
Article
Text
id pubmed-6915746
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-69157462019-12-23 Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials Cheng, Yuan He, Cai Wang, Manni Ma, Xuelei Mo, Fei Yang, Shengyong Han, Junhong Wei, Xiawei Signal Transduct Target Ther Review Article Epigenetic alternations concern heritable yet reversible changes in histone or DNA modifications that regulate gene activity beyond the underlying sequence. Epigenetic dysregulation is often linked to human disease, notably cancer. With the development of various drugs targeting epigenetic regulators, epigenetic-targeted therapy has been applied in the treatment of hematological malignancies and has exhibited viable therapeutic potential for solid tumors in preclinical and clinical trials. In this review, we summarize the aberrant functions of enzymes in DNA methylation, histone acetylation and histone methylation during tumor progression and highlight the development of inhibitors of or drugs targeted at epigenetic enzymes. Nature Publishing Group UK 2019-12-17 /pmc/articles/PMC6915746/ /pubmed/31871779 http://dx.doi.org/10.1038/s41392-019-0095-0 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review Article
Cheng, Yuan
He, Cai
Wang, Manni
Ma, Xuelei
Mo, Fei
Yang, Shengyong
Han, Junhong
Wei, Xiawei
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
title Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
title_full Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
title_fullStr Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
title_full_unstemmed Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
title_short Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
title_sort targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915746/
https://www.ncbi.nlm.nih.gov/pubmed/31871779
http://dx.doi.org/10.1038/s41392-019-0095-0
work_keys_str_mv AT chengyuan targetingepigeneticregulatorsforcancertherapymechanismsandadvancesinclinicaltrials
AT hecai targetingepigeneticregulatorsforcancertherapymechanismsandadvancesinclinicaltrials
AT wangmanni targetingepigeneticregulatorsforcancertherapymechanismsandadvancesinclinicaltrials
AT maxuelei targetingepigeneticregulatorsforcancertherapymechanismsandadvancesinclinicaltrials
AT mofei targetingepigeneticregulatorsforcancertherapymechanismsandadvancesinclinicaltrials
AT yangshengyong targetingepigeneticregulatorsforcancertherapymechanismsandadvancesinclinicaltrials
AT hanjunhong targetingepigeneticregulatorsforcancertherapymechanismsandadvancesinclinicaltrials
AT weixiawei targetingepigeneticregulatorsforcancertherapymechanismsandadvancesinclinicaltrials

Ejemplares similares